AstraZeneca diabetes drug combination faces delay after FDA rebuff

LONDON (Reuters) - U.S. health regulators declined to approve a fixed-dose diabetes drug combination from AstraZeneca , delaying its launch and dealing a blow to an important plank of the drugmaker's business.